How Much Will CMOs Benefit From Biosimilars?

by

Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growth hormones and relatively simple recombinant proteins, have already been approved. Of those first wave biosimilars, 30% have been outsourced to dose manufacturers, and 10% to API manufacturers.

PharmSource’s data-rich Trend Report, Catching a Wave: How Much Will CMOs Benefit From Biosimilars?, concludes that the benefit of biosimilars to the CMO industry is likely to be limited. Biopharma companies or partnerships with significant commercialization and manufacturing capacity are likely to dominate the market for biosimilars and leave the smaller, CMO-dependent companies by the wayside.

More information on Catching a Wave: How Much Will CMOs Benefit From Biosimilars? is available here or by calling PharmSource at +1-703-383-4903.

Read more postings by Jim

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller